BeOne Medicines Ltd. (ONC): Results of Operations and Financial Condition
BeOne Medicines Ltd. (ONC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 BeOne Medicines Announces Second Quarter 2026 Financial Results and Business Updates • Total global revenues of $1.7 billion for the second quarter, an increase of 30% from the prior year • BRUKINSA (zanubrutinib) global revenues of $1.2 billion for the second quarte
How this was made
The 30-second read
Why it matters
The key tradable items are the Q2 performance metrics and the raised FY 2026 revenue and operating income ranges, which directly affect forward estimates and valuation for ONC.
Market read
ONC’s raised FY 2026 revenue guidance and strong Q2 operating leverage provide a fresh catalyst for earnings expectations and near-term positioning.
What to watch
The filing emphasizes BRUKINSA mix and productivity cost improvements; traders should watch for any future margin pressure from mix shifts, competitive dynamics, or higher R&D/SG&A needs as pipeline advances.
BeOne Medicines Announces Second Quarter 2026 Financial Results and Business Updates
Total revenue increased 30%, BRUKINSA global sales increased 31%, GAAP income from operations increased 270%, and the Company raised full-year 2026 total revenue and operating income guidance.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Net product revenues (Q2 2026, unaudited, in thousands of U.S. dollars)other | $1,679,794 | – | 29% |
| Other revenue (Q2 2026, unaudited, in thousands of U.S. dollars)other | $25,277 | – | 91% |
| Total revenue (Q2 2026, unaudited, in thousands of U.S. dollars)other | $1,705,071 | – | 30% |
| GAAP gross margin as a percentage of global product sales (Q2 2026)GAAP | 90% | – | – |
| GAAP research and development expense (Q2 2026, unaudited, in thousands of U.S. dollars)GAAP | $612,280 | – | 17% |
| Non-GAAP research and development expense (Q2 2026, unaudited, in thousands of U.S. dollars)non-GAAP | $533,950 | – | 20% |
| GAAP selling, general and administrative expense (Q2 2026, unaudited, in thousands of U.S. dollars)GAAP | $593,214 | – | 10% |
| Non-GAAP selling, general and administrative expense (Q2 2026, unaudited, in thousands of U.S. dollars)non-GAAP | $500,674 | – | 13% |
| GAAP total operating expenses (Q2 2026, unaudited, in thousands of U.S. dollars)GAAP | $1,205,494 | – | 13% |
| Non-GAAP total operating expenses (Q2 2026, unaudited, in thousands of U.S. dollars)non-GAAP | $1,034,624 | – | 17% |
| GAAP SG&A expenses as a percentage of product sales (Q2 2026)GAAP | 35% | – | – |
| GAAP income from operations (Q2 2026, unaudited, in thousands of U.S. dollars)GAAP | $325,047 | – | 270% |
| Adjusted income from operations (Q2 2026, unaudited, in thousands of U.S. dollars)non-GAAP | $503,029 | – | 83% |
| GAAP net income (Q2 2026, unaudited, in thousands of U.S. dollars)GAAP | $237,007 | – | 151% |
| Adjusted net income (Q2 2026, unaudited, in thousands of U.S. dollars)non-GAAP | $444,497 | – | 76% |
| GAAP basic EPS per ADS (Q2 2026)GAAP | $2.12 | – | 144% |
| Adjusted basic EPS per ADS (Q2 2026)non-GAAP | $3.98 | – | 71% |
| GAAP diluted EPS per ADS (Q2 2026)GAAP | $2.05 | – | 144% |
| Adjusted diluted EPS per ADS (Q2 2026)non-GAAP | $3.84 | – | 71% |
| Free Cash Flow (Q2 2026, unaudited, in thousands of U.S. dollars)non-GAAP | $435,344 | – | 98% |
| Net product revenues (six months ended June 30, 2026, unaudited, in thousands of U.S. dollars)other | $3,167,123 | – | 31% |
| Other revenue (six months ended June 30, 2026, unaudited, in thousands of U.S. dollars)other | $51,386 | – | 134% |
| Total revenue (six months ended June 30, 2026, unaudited, in thousands of U.S. dollars)other | $3,218,509 | – | 32% |
| GAAP income from operations (six months ended June 30, 2026, unaudited, in thousands of U.S. dollars)GAAP | $574,949 | – | 481% |
| Adjusted income from operations (six months ended June 30, 2026, unaudited, in thousands of U.S. dollars)non-GAAP | $917,423 | – | 121% |
| GAAP net income (six months ended June 30, 2026, unaudited, in thousands of U.S. dollars)GAAP | $464,364 | – | 386% |
| Adjusted net income (six months ended June 30, 2026, unaudited, in thousands of U.S. dollars)non-GAAP | $819,539 | – | 111% |
| GAAP basic EPS per ADS (six months ended June 30, 2026)GAAP | $4.17 | – | 369% |
| Adjusted basic EPS per ADS (six months ended June 30, 2026)non-GAAP | $7.37 | – | 104% |
| GAAP diluted EPS per ADS (six months ended June 30, 2026)GAAP | $4.01 | – | 372% |
| Adjusted diluted EPS per ADS (six months ended June 30, 2026)non-GAAP | $7.08 | – | 103% |
| Free Cash Flow (six months ended June 30, 2026, unaudited, in thousands of U.S. dollars)non-GAAP | $595,891 | – | 187% |
| GAAP research and development expense (first half of 2026, unaudited, in thousands of U.S. dollars)GAAP | $1,153,504 | – | 15% |
| Non-GAAP research and development expense (first half of 2026, unaudited, in thousands of U.S. dollars)non-GAAP | $999,854 | – | 16% |
| GAAP selling, general and administrative expense (first half of 2026, unaudited, in thousands of U.S. dollars)GAAP | $1,148,311 | – | 15% |
| Non-GAAP selling, general and administrative expense (first half of 2026, unaudited, in thousands of U.S. dollars)non-GAAP | $972,667 | – | 16% |
| GAAP total operating expenses (first half of 2026, unaudited, in thousands of U.S. dollars)GAAP | $2,301,815 | – | 15% |
| Non-GAAP total operating expenses (first half of 2026, unaudited, in thousands of U.S. dollars)non-GAAP | $1,972,521 | – | 16% |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| BRUKINSA (zanubrutinib) global salesThe Company cited BRUKINSA's leadership position in the U.S. and continued global expansion in both Europe and other important rest of world markets as drivers of expected full-year revenue growth. | $1.2 billion | – | 31% |
| BRUKINSA (zanubrutinib) U.S. salesBRUKINSA continued to gain momentum, according to the Company. | $893 million | – | 31% |
| TEVIMBRA (tislelizumab) global salesThe Company received Japan regulatory approval for the treatment of adult patients with first-line gastric cancer. | $229 million | – | 18% |
| Amgen in-licensed products global salesNo specific sales driver was provided. | $157 million | – | 25% |
FY 2026 outlook
- Revenue$6.6B - $6.8B
- Gross marginHigh-80% range
- Operating expenses$4.8B - $5.0B
- NoteGAAP operating income: $1.0B - $1.1B
- NoteNon-GAAP operating income: $1.7B - $1.8B
- NoteOther income (expense): Estimated range of $25 million to $50 million in expense
- NoteDiluted ADSs outstanding: approximately 118 million
- NoteAssumes August 1, 2026 foreign exchange rates.
- NoteGuidance does not assume any potential new, material business development activity or unusual/non-recurring items.
What drove it
- Total revenue increased 30% from the prior-year period, led by 29% growth in net product revenues and 91% growth in other revenue.
- Gross margin increased to 90% from 87% on a GAAP basis due to a proportionally higher sales mix of global BRUKINSA and productivity improvements resulting in lower costs for both BRUKINSA and TEVIMBRA.
- GAAP net income increased primarily due to revenue growth and improved operating leverage.
- R&D expense increased due to advancing early clinical programs into late stage and preclinical programs into the clinic.
- SG&A expense increased due to continued investment to support commercial growth.
- BRUKINSA reported positive topline results from the Phase 3 MANGROVE study and long-term 78-month follow-up data from the Phase 3 SEQUOIA study.
- BEQALZI received U.S. FDA accelerated approval for adult patients with relapsed or refractory MCL after at least two lines of systemic therapy, including a BTK inhibitor.
Concerns
- GAAP R&D expense increased 17% and GAAP SG&A expense increased 10% from the prior-year period.
- Upfront fees and milestone payments related to in-process R&D for in-licensed assets totaled $23.3 million in the second quarter of 2026, compared to $0.5 million in the second quarter of 2025.
- Estimated other income (expense) is $25 million to $50 million in expense and includes interest amortization from the Royalty Pharma arrangement.
- The timing and magnitude of a potential reversal of certain valuation allowances is uncertain.
- Full-year guidance does not assume potential new, material business development activity or unusual/non-recurring items.
What to watch
- Regulatory submissions for BRUKINSA in first-line MCL in the U.S., Europe, China and Japan in 2H 2026.
- U.S. FDA regulatory action for TEVIMBRA in first-line HER2-positive GEA in combination with ZIIHERA and chemotherapy in 2H 2026.
- China regulatory action for TEVIMBRA and ZIIHERA in first-line HER2-positive GEA in combination with ZIIHERA and chemotherapy in 1H 2027.
- Whether earnings provide sufficient positive evidence to reverse certain valuation allowances in 2026.
- Delivery against FY 2026 total revenue guidance of $6.6B - $6.8B and GAAP operating income guidance of $1.0B - $1.1B.
Balance sheet and cash flow
- Free Cash Flow for the second quarter of 2026 was $435 million, representing an increase of $216 million over the prior-year period.
- Free Cash Flow (six months ended June 30, 2026, unaudited, in thousands of U.S. dollars): $595,891, compared to $207,447, an increase of 187%.
Analysis
BeOne reported a strong second quarter, with total revenue of $1,705,071 in thousands of U.S. dollars, up 30% from $1,315,300. Net product revenues rose 29% to $1,679,794, while other revenue increased 91% to $25,277. BRUKINSA global sales totaled $1.2 billion, up 31%, including U.S. sales of $893 million, also up 31%. TEVIMBRA global sales increased 18% to $229 million, and Amgen in-licensed products global sales increased 25% to $157 million.
Profitability expanded faster than revenue. GAAP gross margin increased to 90% from 87%, reflecting a higher proportion of global BRUKINSA sales and lower costs for BRUKINSA and TEVIMBRA from productivity improvements. GAAP income from operations increased 270% to $325,047 in thousands of U.S. dollars, while adjusted income from operations increased 83% to $503,029. GAAP SG&A expense as a percentage of product sales declined to 35% from 41%, supporting the Company's stated improved operating leverage.
The Company continued to invest in commercial expansion and development. GAAP R&D expense increased 17% to $612,280 in thousands of U.S. dollars as early clinical programs advanced into late stage and preclinical programs entered the clinic. GAAP SG&A expense increased 10% to $593,214. In-process R&D upfront fees and milestone payments for in-licensed assets were $23.3 million, compared with $0.5 million in the prior-year period. GAAP net income increased 151% to $237,007, adjusted net income increased 76% to $444,497, and free cash flow increased 98% to $435,344.
Management raised FY 2026 total revenue guidance to $6.6B - $6.8B from $6.3B - $6.5B. It also raised GAAP operating income guidance to $1.0B - $1.1B from $750M - $850M and non-GAAP operating income guidance to $1.7B - $1.8B from $1.45B - $1.55B. The Company maintained guidance for GAAP gross margin in the high-80% range and increased expected GAAP combined R&D and SG&A expense to $4.8B - $5.0B from $4.7B - $4.9B.
Clinical and regulatory progress accompanied the financial results. BRUKINSA generated positive Phase 3 MANGROVE topline results, BEQALZI received U.S. FDA accelerated approval in relapsed or refractory MCL, and TEVIMBRA received Japan regulatory approval in first-line gastric cancer. Near-term attention centers on BRUKINSA first-line MCL regulatory submissions in 2H 2026, the U.S. FDA action for TEVIMBRA plus ZIIHERA and chemotherapy in first-line HER2-positive GEA in 2H 2026, and the uncertain timing and magnitude of a possible valuation-allowance reversal.
Management, verbatim
These strong second-quarter results underscore our continued growth as a global oncology leader. Our foundational hematology franchise, led by BRUKINSA, continues to gain momentum as we advance one of the industry’s deepest and most diverse pipelines. With differentiated capabilities spanning drug discovery, clinical development, manufacturing, and commercialization, we are well positioned for our next phase of global growth.
John V. Oyler, Co-Founder, Chairman, and CEO, BeOne
Not in the filing
stated, not guessed- Prior-quarter revenue, operating income, net income, EPS, operating expense, gross-margin, and free-cash-flow comparisons
- Cash balance
- Debt balance
- Operating cash flow
- Capital expenditures
- Share repurchases
- Dividends
- Actual income tax expense and tax rate
- Formal reportable-segment revenue disclosure
- A separately provided previous-release outlook section for actual-versus-prior-guidance comparison
AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
This is an SEC 8-K with Exhibit 99.1 covering BeOne Medicines’ Q2 2026 financial results and business updates, including updated full-year 2026 guidance.
Ticker impact
BeOne reported Q2 2026 results and raised full-year 2026 revenue guidance to $6.6B-$6.8B, driven by BRUKINSA growth.
Likely positive bias for ONC into the next trading sessions as traders price the higher 2026 revenue and operating income range.
The filing discloses both quarterly financials (revenue, GAAP/non-GAAP operating income, EPS, free cash flow) and a specific, updated FY 2026 guidance range, which is actionable for valuation and positioning.
Market effects
Reinforces demand and commercial momentum for BTK/hematology oncology franchises, potentially supporting sentiment toward similar revenue-growth oncology names.
Limited direct regional spillover; guidance and results are company-specific but can influence US small/mid-cap biotech sentiment.
Global revenue growth and commercialization updates may modestly affect broader oncology investor risk appetite, but impact is primarily ONC-specific.
Counterpoint
The guidance raise may already be partially anticipated; investors could focus on sustainability of BRUKINSA mix and whether operating leverage can persist.
Key entities
- issuerBeOne Medicines Ltd.
NASDAQ-listed oncology company reporting Q2 2026 results and raising FY 2026 guidance.
- productBRUKINSA (zanubrutinib)
BeOne’s hematology franchise; Q2 2026 global sales were $1.2B, up 31% YoY.
